Rapamycin Quiets the Aging Immune System Around Arterial Plaques

News
#1

RapamycinCVD
RapamycinCVD2752Ă—1536 435 KB

Researchers at Leiden University gave rapamycin to naturally aged male mice that already had advanced atherosclerosis. After eight weeks, plaque size, collagen and necrotic core were unchanged. The immune environment was substantially remodeled. Plaque macrophage staining fell about 23 percent. Aortic neutrophils and CD8 T cells dropped. Regulatory T cells rose as a share of helper T cells. Germinal center B cells, antibody levels and age-associated B cells fell sharply in plaque-draining lymph nodes. Some senescence markers declined. The costs were a 25 percent rise in blood cholesterol and broad suppression of antibody-producing immunity.

Rapamycin has spent two decades as the most reliable lifespan-extending drug in mice, and a growing number of people take it off-label hoping to slow their own aging. A new study from Leiden University asks a narrower, clinically pointed question: what does the drug do to the immune system of an old animal that already has advanced arterial disease?

The answer is that it reshapes that immune system substantially, but it does not shrink the plaques.

The team used male mice lacking the LDL receptor, a standard model for human-like cholesterol problems. The mice aged on ordinary chow until they were 80 to 90 weeks old, roughly comparable to people in their late fifties to mid-sixties. By then the animals carried arterial plaques built up slowly over a lifetime rather than forced by a high-fat diet. Half then received rapamycin injections three times a week for eight weeks. The others received a placebo solution.

Plaque size did not change. Neither did collagen content or the necrotic core, the dead, debris-filled center that makes human plaques prone to rupture. What changed was the cellular makeup. Rapamycin-treated plaques held about 23 percent less macrophage staining. Macrophages are the immune cells that swallow cholesterol and become foam cells. In the aortic wall, neutrophils dropped by roughly two-thirds and killer CD8 T cells by more than half. Meanwhile, the share of regulatory T cells, which calm inflammation and are thought to help stabilize plaques, rose from about 57 to 71 percent of helper T cells.

The effects were much larger in the lymph nodes that drain the heart and aorta. There, total immune cell counts fell almost six-fold. Germinal centers are the lymph node sites where B cells learn to make high-affinity antibodies, and they all but disappeared. Blood levels of IgM and several IgG subclasses fell by 40 to 60 percent. Age-associated B cells also declined. These cells accumulate with age and are linked to autoimmunity and chronic inflammation.

Gene expression hinted at a partial rollback of immune aging. Senescence scores fell in several aortic immune cell types. Spleen cells expressed less p16 and Btg2, two hallmarks of aging cells. Two other senescence markers, p21 and p53, did not change.

The trade-offs are real. Blood cholesterol rose 25 percent, a side effect already well documented in transplant patients on mTOR inhibitors. The same suppression of germinal centers and antibodies that looks anti-inflammatory inside an artery could weaken responses to vaccines and infections in an older person. The spleen also showed more interferon-gamma-producing helper T cells, and more helper T cells that had lost CD27, a marker of heavily used, late-stage cells.

The authors present the work as a case for “immune rejuvenation” in older cardiovascular patients, possibly combined with statins to offset the cholesterol rise. The study shows a quieter, more regulated immune landscape around established plaques. It does not show that plaques grew less, or that the mice had fewer cardiac events or lived longer. Those are the outcomes that ultimately matter.

Actionable Insights

This is a short mouse study with no clinical endpoints. It supports hypotheses, not prescriptions. With that caveat, four practical points emerge.

First, do not expect rapamycin alone to shrink existing plaque. What improved was plaque inflammation. Macrophage content fell about 23 percent, a moderate-to-large effect (a treated mouse had roughly a 71 percent chance of scoring better than a control).

Second, monitor lipids. Total cholesterol rose 25 percent, from about 258 to 323 mg/dL. That is a large effect (roughly an 83 percent chance a treated mouse ran higher than a control), and it matches human transplant data. Anyone using rapamycin who has cardiovascular concerns should track an ApoB or lipid panel. Pairing with lipid-lowering therapy deserves a conversation with a clinician.

Third, consider vaccine timing. Germinal center B cells in the draining lymph nodes fell about 97 percent, and IgM fell about 61 percent. This used a fairly intense regimen, and low-dose human trials have shown better vaccine responses, so dose and schedule likely matter.

Fourth, the regulatory T cell shift (up about 13 percentage points) is the most plausible benefit mechanism, but it remains unproven in humans.

Context and Source

1 Like
#2

Study Design Specifications

  • Type: In vivo intervention study, with supporting in vitro splenocyte assays and reanalysis of existing human and mouse single-cell datasets.
  • Species and strain: Mouse, Ldlr knockout on a C57BL/6 background (Jackson Laboratory, bred and aged in-house).
  • Sex: Male only in the intervention arm. The reference mouse scRNA-seq dataset used for Mtor expression was female.
  • Age at start: 80 to 90 weeks. The paper also states “80 weeks” in Figure 2, “20 months” in Figure 3 and “75 to 95 weeks” in the scRNA-seq methods.
  • Diet: Standard chow for the entire lifespan, with no Western diet.
  • Intervention: Rapamycin 1 mg/kg intraperitoneally, three times weekly for 8 weeks. The vehicle was 1% DMSO, 5% PEG300 and 5% Tween-80 in PBS.

Biomarker Data (Effect Size Extraction)

How to read this table: Cohen’s d measures how far apart two group averages are, in units of the natural spread between individual animals. As a rule of thumb, 0.2 is small, 0.5 is medium, 0.8 is large and above 1.2 is very large. Another way to picture it: a d of 0.8 means a randomly chosen treated mouse has about a 71 percent chance of beating a randomly chosen control. At d = 2 that rises to about 92 percent.

I calculated these values from the reported means and standard errors, assuming n = 12 per group. Small samples tend to inflate d, and the authors removed statistical outliers, which inflates it further. Treat every value below as an upper-leaning estimate.

Outcome (tissue) Control Rapamycin Change Cohen’s d (approx.) Direction
Plaque size, collagen, necrotic core (aortic root) no difference no difference about 0% about 0 Neutral
Plaque macrophage area (aortic root, x10^5 square microns) 0.95 0.73 -23% 0.8 Beneficial
Total serum cholesterol (mg/dL) 258 323 +25% 1.35 Adverse
Total aortic CD45+ leukocytes (count) 3127 2046 -35% (p = 0.07) 0.76 Beneficial trend
Aortic neutrophils (count) 55 20 -64% 0.8 Beneficial
Aortic CD8+ T cells (count) 396 180 -55% 1.5 Likely beneficial
Aortic Tregs (% of CD4+) 57.1% 70.6% +13.5 points 1.15 Beneficial
Lymph node total leukocytes (x10^4) 9.9 1.7 -83% (5.8-fold) 2.2 Mixed
Lymph node Tregs (% of CD4+) 37.2% 49.7% +12.5 points 2.2 Beneficial
Lymph node germinal center B cells (% of B cells) 1.16% 0.04% -97% 2.0 Mixed
Serum IgM (ng/mL) 106 41.5 -61% 1.75 Mixed
Serum IgG1 (ng/mL) 5.51 2.89 -48% 1.3 Mixed
Spleen Tfh cells (% of CD4+) 10.8% 7.1% -35% 2.0 Mixed
Spleen Il21 expression 1.9 0.65 -66% 1.9 Mixed
Spleen Tregs (% of CD4+) 34.8% 38.7% +3.9 points 0.9 Beneficial
Spleen p16 (Cdkn2a) expression 2.23 1.70 -24% 1.0 Beneficial
Spleen Btg2 expression 0.040 0.031 -23% 0.9 Beneficial
Spleen p21, p53 expression no difference no difference about 0% about 0 Neutral
Spleen CD27-negative CD4+ T cells (%) 19.2% 28.2% +47% relative 1.4 Possibly adverse
Spleen IFN-gamma+ CD4+ T cells, stimulated (%) 9.5% 15.4% +62% relative 1.8 Possibly adverse
Spleen myeloid cells (x10^6) 0.59 1.10 +86% 1.6 Unclear

“Mixed” marks outcomes that reduce inflammation in the artery but could also weaken protective immunity.

In plain terms, the most clinically relevant single benefit, lower plaque macrophage content, is a real but moderate effect. The largest effects fall on lymphoid tissue and antibody production. These are exactly the effects that raise immunosuppression concerns. The cholesterol rise is larger in standardized terms than the plaque macrophage benefit [Confidence: Medium].

Novelty

  • This is the first test of rapamycin in naturally aged, chow-fed atherosclerotic mice, rather than young mice on accelerated Western diets. That is more relevant to how human disease develops [Confidence: High].
  • It provides the first single-cell map of how rapamycin reshapes plaque-resident immune cells in aged animals [Confidence: High].
  • It shows that MTOR is broadly expressed in human carotid plaque leukocytes, with B cells among the highest expressers (descriptive only).
  • It shows that rapamycin nearly abolishes germinal center B cells in plaque-draining lymph nodes, and it reduces oxidation-specific epitope antibodies (anti-MDA and anti-oxLDL). Some of these antibodies, particularly IgM, are considered atheroprotective, so this is a double-edged finding.
  • It documents a reduction in age-associated B cells in an atherosclerosis setting.
  • It dissociates immune remodeling from plaque burden. Eight weeks of treatment changed composition without changing size.

Bayesian Bottom Line:

Prior belief that mTOR inhibition reduces vascular inflammation in mice was already moderately high, based on young-mouse and stent data. This study raises confidence that the effect persists in aged animals with established disease [Confidence: Medium-High]. It adds little evidence that plaque burden or clinical risk improves [Confidence: Low]. It strengthens the prior that meaningful trade-offs in lipids and humoral immunity accompany continuous dosing [Confidence: Medium-High]. For humans, the relevant open question is whether low, intermittent oral dosing can capture the regulatory T cell and anti-senescence shifts while avoiding the germinal center and lipid costs. This study was not designed to answer that.

1 Like